Free Trial

Disc Medicine (IRON) Stock Price, News & Analysis

Disc Medicine logo
$67.78 +1.92 (+2.92%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$67.75 -0.03 (-0.04%)
As of 10/3/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Disc Medicine Stock (NASDAQ:IRON)

Advanced

Key Stats

Today's Range
$65.43
$67.92
50-Day Range
$57.07
$67.78
52-Week Range
$30.82
$68.79
Volume
272,220 shs
Average Volume
380,936 shs
Market Capitalization
$2.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$98.30
Consensus Rating
Moderate Buy

Company Overview

Disc Medicine Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

IRON MarketRank™: 

Disc Medicine scored higher than 40% of companies evaluated by MarketBeat, and ranked 695th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Disc Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 10 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Disc Medicine has a consensus price target of $98.30, representing about 45.0% upside from its current price of $67.78.

  • Amount of Analyst Coverage

    Disc Medicine has only been the subject of 4 research reports in the past 90 days.

  • Read more about Disc Medicine's stock forecast and price target.
  • Earnings Growth

    Earnings for Disc Medicine are expected to decrease in the coming year, from ($4.07) to ($5.01) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Disc Medicine is -15.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Disc Medicine is -15.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Disc Medicine has a P/B Ratio of 4.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Disc Medicine's valuation and earnings.
  • Percentage of Shares Shorted

    9.76% of the float of Disc Medicine has been sold short.
  • Short Interest Ratio / Days to Cover

    Disc Medicine has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in Disc Medicine has recently increased by 6.67%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Disc Medicine does not currently pay a dividend.

  • Dividend Growth

    Disc Medicine does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.76% of the float of Disc Medicine has been sold short.
  • Short Interest Ratio / Days to Cover

    Disc Medicine has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in Disc Medicine has recently increased by 6.67%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Disc Medicine this week, compared to 6 articles on an average week.
  • Search Interest

    Only 2 people have searched for IRON on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Disc Medicine to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,465,583.00 in company stock.

  • Percentage Held by Insiders

    Only 3.64% of the stock of Disc Medicine is held by insiders.

  • Percentage Held by Institutions

    83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Disc Medicine's insider trading history.
Receive IRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IRON Stock News Headlines

URGENT: The Market's 3 Red Flags Are Flashing
Here’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash before 2025 ends.tc pixel
Disc Medicine (IRON) Receives a Buy from TD Cowen
Disc Medicine (IRON) Receives a Buy from Truist Financial
See More Headlines

IRON Stock Analysis - Frequently Asked Questions

Disc Medicine's stock was trading at $63.40 at the beginning of 2025. Since then, IRON stock has increased by 6.9% and is now trading at $67.78.

Disc Medicine, Inc. (NASDAQ:IRON) posted its quarterly earnings results on Thursday, August, 7th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.17) by $0.41.

Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL).

Company Calendar

Last Earnings
8/07/2025
Today
10/05/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IRON
CIK
1816736
Fax
N/A
Employees
30
Year Founded
2017

Price Target and Rating

High Price Target
$132.00
Low Price Target
$75.00
Potential Upside/Downside
+45.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$109.36 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-26.60%
Return on Assets
-24.58%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
32.11
Quick Ratio
32.11

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$14.85 per share
Price / Book
4.56

Miscellaneous

Outstanding Shares
34,770,000
Free Float
33,501,000
Market Cap
$2.36 billion
Optionable
Not Optionable
Beta
0.80

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:IRON) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners